Document
1false--12-31Q32019000157477467202000742410002534500026504000268000920000.0010.001200000000200000000334063643399110733406364P3YP2Y100000000 0001574774 2019-01-01 2019-09-30 0001574774 beat:GenevaHealthcareInc.Member 2019-01-01 2019-09-30 0001574774 us-gaap:OtherNoncurrentLiabilitiesMember 2019-01-01 2019-09-30 0001574774 2019-10-28 0001574774 2018-12-31 0001574774 2019-09-30 0001574774 2018-01-01 2018-09-30 0001574774 2018-07-01 2018-09-30 0001574774 2019-07-01 2019-09-30 0001574774 2018-09-30 0001574774 2017-12-31 0001574774 us-gaap:CommonStockMember 2018-09-30 0001574774 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001574774 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001574774 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001574774 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001574774 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001574774 us-gaap:RetainedEarningsMember 2018-09-30 0001574774 us-gaap:CommonStockMember 2017-12-31 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001574774 us-gaap:NoncontrollingInterestMember 2018-09-30 0001574774 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-09-30 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001574774 us-gaap:NoncontrollingInterestMember 2017-12-31 0001574774 us-gaap:RetainedEarningsMember 2017-12-31 0001574774 2018-06-30 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001574774 us-gaap:RetainedEarningsMember 2018-06-30 0001574774 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001574774 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001574774 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001574774 us-gaap:CommonStockMember 2018-06-30 0001574774 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001574774 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001574774 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001574774 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001574774 us-gaap:CommonStockMember 2018-12-31 0001574774 us-gaap:CommonStockMember 2019-09-30 0001574774 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001574774 us-gaap:RetainedEarningsMember 2019-09-30 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001574774 us-gaap:RetainedEarningsMember 2018-12-31 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001574774 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001574774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001574774 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001574774 us-gaap:CommonStockMember 2019-06-30 0001574774 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001574774 2019-06-30 0001574774 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001574774 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001574774 us-gaap:RetainedEarningsMember 2019-06-30 0001574774 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001574774 us-gaap:AccountsReceivableMember beat:PayorConcentrationRiskMember beat:ThirdPartyPayorMedicareMember beat:PatientServiceSegmentMember 2018-01-01 2018-12-31 0001574774 us-gaap:AccountsReceivableMember beat:PayorConcentrationRiskMember beat:ThirdPartyPayorMedicareMember beat:PatientServiceSegmentMember 2019-01-01 2019-09-30 0001574774 us-gaap:AccountsReceivableMember beat:PayorConcentrationRiskMember beat:ThirdPartyPayorMedicareMember beat:PatientServiceSegmentMember 2019-09-30 0001574774 us-gaap:AccountsReceivableMember beat:PayorConcentrationRiskMember beat:ThirdPartyPayorMedicareMember beat:PatientServiceSegmentMember 2018-12-31 0001574774 beat:CorporateAndReconcilingItemsMember 2018-07-01 2018-09-30 0001574774 beat:CorporateAndReconcilingItemsMember beat:TechnologyDevicesConsumablesandRelatedServicesMember 2018-07-01 2018-09-30 0001574774 beat:TechnologyDevicesConsumablesandRelatedServicesMember 2018-07-01 2018-09-30 0001574774 beat:MonitoringCommercialMember 2018-07-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:MonitoringCommercialMember beat:PatientServiceSegmentMember 2018-07-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:ResearchServicesMember 2018-07-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:PatientServiceSegmentMember 2018-07-01 2018-09-30 0001574774 beat:ClinicalTrialSupportandRelatedServicesMember 2018-07-01 2018-09-30 0001574774 beat:MonitoringMedicareMember 2018-07-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:MonitoringMedicareMember beat:PatientServiceSegmentMember 2018-07-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:ClinicalTrialSupportandRelatedServicesMember beat:ResearchServicesMember 2018-07-01 2018-09-30 0001574774 beat:TechnologyDevicesConsumablesandRelatedServicesMember 2019-01-01 2019-09-30 0001574774 beat:MonitoringCommercialMember 2019-01-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:ClinicalTrialSupportandRelatedServicesMember beat:ResearchServicesMember 2019-01-01 2019-09-30 0001574774 beat:ClinicalTrialSupportandRelatedServicesMember 2019-01-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:MonitoringCommercialMember beat:PatientServiceSegmentMember 2019-01-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:MonitoringMedicareMember beat:PatientServiceSegmentMember 2019-01-01 2019-09-30 0001574774 beat:CorporateAndReconcilingItemsMember beat:TechnologyDevicesConsumablesandRelatedServicesMember 2019-01-01 2019-09-30 0001574774 beat:MonitoringMedicareMember 2019-01-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:PatientServiceSegmentMember 2019-01-01 2019-09-30 0001574774 beat:CorporateAndReconcilingItemsMember 2019-01-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:ResearchServicesMember 2019-01-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:MonitoringCommercialMember beat:PatientServiceSegmentMember 2018-01-01 2018-09-30 0001574774 beat:ClinicalTrialSupportandRelatedServicesMember 2018-01-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:ResearchServicesMember 2018-01-01 2018-09-30 0001574774 beat:MonitoringMedicareMember 2018-01-01 2018-09-30 0001574774 beat:TechnologyDevicesConsumablesandRelatedServicesMember 2018-01-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:PatientServiceSegmentMember 2018-01-01 2018-09-30 0001574774 beat:MonitoringCommercialMember 2018-01-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:MonitoringMedicareMember beat:PatientServiceSegmentMember 2018-01-01 2018-09-30 0001574774 beat:CorporateAndReconcilingItemsMember beat:TechnologyDevicesConsumablesandRelatedServicesMember 2018-01-01 2018-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:ClinicalTrialSupportandRelatedServicesMember beat:ResearchServicesMember 2018-01-01 2018-09-30 0001574774 beat:CorporateAndReconcilingItemsMember 2018-01-01 2018-09-30 0001574774 beat:CorporateAndReconcilingItemsMember beat:TechnologyDevicesConsumablesandRelatedServicesMember 2019-07-01 2019-09-30 0001574774 beat:MonitoringMedicareMember 2019-07-01 2019-09-30 0001574774 beat:TechnologyDevicesConsumablesandRelatedServicesMember 2019-07-01 2019-09-30 0001574774 beat:ClinicalTrialSupportandRelatedServicesMember 2019-07-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:MonitoringCommercialMember beat:PatientServiceSegmentMember 2019-07-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:ClinicalTrialSupportandRelatedServicesMember beat:ResearchServicesMember 2019-07-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:MonitoringMedicareMember beat:PatientServiceSegmentMember 2019-07-01 2019-09-30 0001574774 beat:MonitoringCommercialMember 2019-07-01 2019-09-30 0001574774 beat:CorporateAndReconcilingItemsMember 2019-07-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:PatientServiceSegmentMember 2019-07-01 2019-09-30 0001574774 us-gaap:OperatingSegmentsMember beat:ResearchServicesMember 2019-07-01 2019-09-30 0001574774 beat:GenevaHealthcareInc.Member 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member us-gaap:TradeNamesMember 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member us-gaap:TechnologyBasedIntangibleAssetsMember 2019-03-01 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member us-gaap:CustomerRelationshipsMember 2019-03-01 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member us-gaap:TechnologyBasedIntangibleAssetsMember 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member us-gaap:TradeNamesMember 2019-03-01 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member us-gaap:CustomerRelationshipsMember 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member beat:PatientServiceSegmentMember 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member 2019-03-01 2019-03-01 0001574774 beat:GenevaHealthcareInc.Member beat:PatientServiceSegmentMember 2019-01-01 2019-09-30 0001574774 beat:ADEAMedicalIncMember beat:SalesRestrictionEnding2Q2022Member 2019-04-01 2019-06-30 0001574774 beat:ADEAMedicalIncMember beat:SalesRestrictionEnding4Q2019Member 2019-04-01 2019-06-30 0001574774 beat:ADEAMedicalIncMember 2019-04-01 2019-06-30 0001574774 beat:ADEAMedicalIncMember 2019-06-30 0001574774 beat:GenevaHealthcareInc.Member beat:PatientServiceSegmentMember 2019-04-01 2019-06-30 0001574774 beat:ADEAMedicalIncMember 2019-03-31 0001574774 beat:ActiveCareMember us-gaap:FairValueInputsLevel3Member 2018-10-02 0001574774 beat:GenevaHealthcareInc.Member us-gaap:FairValueInputsLevel3Member 2019-03-01 0001574774 beat:ADEAMedicalIncMember beat:PatientServiceSegmentMember 2019-06-30 0001574774 beat:ActiveCareMember 2018-10-02 2018-10-02 0001574774 srt:MaximumMember beat:ActiveCareMember 2018-10-02 0001574774 beat:ContingentConsiderationLiabilityMember 2019-09-30 0001574774 beat:ContingentConsiderationLiabilityMember 2019-01-01 2019-09-30 0001574774 beat:ContingentConsiderationLiabilityMember 2018-01-01 2018-09-30 0001574774 beat:ContingentConsiderationLiabilityMember 2018-07-01 2018-09-30 0001574774 beat:ContingentConsiderationLiabilityMember 2018-09-30 0001574774 beat:ContingentConsiderationLiabilityMember 2018-12-31 0001574774 beat:ContingentConsiderationLiabilityMember 2019-07-01 2019-09-30 0001574774 beat:ContingentConsiderationLiabilityMember 2019-06-30 0001574774 beat:ContingentConsiderationLiabilityMember 2017-12-31 0001574774 beat:ContingentConsiderationLiabilityMember 2018-06-30 0001574774 beat:GenevaHealthcareInc.Member us-gaap:FairValueInputsLevel3Member beat:ContingentConsiderationLiabilityMember 2019-01-01 2019-09-30 0001574774 us-gaap:FairValueInputsLevel2Member 2019-09-30 0001574774 beat:TelcareIncMember us-gaap:FairValueInputsLevel3Member beat:ContingentConsiderationLiabilityMember 2018-01-01 2018-09-30 0001574774 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001574774 us-gaap:CustomerRelationshipsMember 2018-12-31 0001574774 beat:BacklogMember 2019-09-30 0001574774 beat:BacklogMember 2019-01-01 2019-09-30 0001574774 us-gaap:TradeNamesMember 2018-12-31 0001574774 us-gaap:TradeNamesMember 2019-09-30 0001574774 us-gaap:NoncompeteAgreementsMember 2019-01-01 2019-09-30 0001574774 us-gaap:DevelopedTechnologyRightsMember 2019-09-30 0001574774 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-09-30 0001574774 us-gaap:NoncompeteAgreementsMember 2018-12-31 0001574774 us-gaap:TradeNamesMember 2019-01-01 2019-09-30 0001574774 us-gaap:CustomerRelationshipsMember 2019-09-30 0001574774 beat:BacklogMember 2018-12-31 0001574774 us-gaap:NoncompeteAgreementsMember 2019-09-30 0001574774 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-09-30 0001574774 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001574774 beat:PatientServiceSegmentMember 2019-01-01 2019-09-30 0001574774 beat:ResearchServicesMember 2018-12-31 0001574774 us-gaap:CorporateAndOtherMember 2019-09-30 0001574774 us-gaap:CorporateAndOtherMember 2018-12-31 0001574774 beat:ResearchServicesMember 2019-01-01 2019-09-30 0001574774 us-gaap:CorporateAndOtherMember 2019-01-01 2019-09-30 0001574774 beat:ResearchServicesMember 2019-09-30 0001574774 beat:PatientServiceSegmentMember 2019-09-30 0001574774 beat:PatientServiceSegmentMember 2018-12-31 0001574774 beat:ADEAMedicalIncMember 2018-10-31 2018-10-31 0001574774 beat:WellBridgeHealthIncMember 2019-09-30 0001574774 us-gaap:RevolvingCreditFacilityMember beat:SuntrustBankMember 2019-01-01 2019-09-30 0001574774 beat:SuntrustBankMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-09-30 0001574774 beat:SuntrustBankMember us-gaap:BaseRateMember 2019-01-01 2019-09-30 0001574774 us-gaap:RevolvingCreditFacilityMember beat:SuntrustBankMember 2017-07-12 0001574774 us-gaap:SecuredDebtMember beat:SuntrustBankMember 2019-09-30 0001574774 us-gaap:SecuredDebtMember beat:SuntrustBankMember 2017-07-12 0001574774 beat:LifeWatchMember 2018-01-01 2018-09-30 0001574774 beat:GenevaHealthcareInc.Member 2019-07-01 2019-09-30 0001574774 beat:LifeWatchMember 2019-07-01 2019-09-30 0001574774 beat:GenevaHealthcareInc.Member 2018-01-01 2018-09-30 0001574774 beat:LifeWatchMember 2019-01-01 2019-09-30 0001574774 beat:LifeWatchMember 2018-07-01 2018-09-30 0001574774 beat:GenevaHealthcareInc.Member 2018-07-01 2018-09-30 0001574774 beat:PerformanceStockOptionMember 2019-09-30 0001574774 beat:PerformanceStockOptionMember 2019-01-01 2019-09-30 0001574774 beat:PerformanceStockOptionMember 2018-12-31 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2019-07-01 2019-09-30 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2018-01-01 2018-09-30 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2019-01-01 2019-09-30 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2018-07-01 2018-09-30 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2019-09-30 0001574774 srt:MaximumMember beat:EmployeeDirectorAndConsultantStockOptionsMember 2019-01-01 2019-09-30 0001574774 us-gaap:EmployeeStockMember 2017-05-31 0001574774 beat:PerformanceStockUnitsMember 2019-01-01 2019-09-30 0001574774 beat:A2017OmnibusIncentivePlanMember 2019-09-30 0001574774 us-gaap:EmployeeStockMember 2019-09-30 0001574774 beat:EquityIncentivePlan2008Member 2019-09-30 0001574774 us-gaap:EmployeeStockMember 2017-05-01 2017-05-31 0001574774 us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0001574774 beat:PerformanceStockUnitsMember 2018-12-31 0001574774 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001574774 beat:PerformanceStockUnitsMember 2019-09-30 0001574774 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0001574774 us-gaap:EmployeeStockMember 2018-07-01 2018-09-30 0001574774 beat:PerformanceStockUnitsMember 2018-07-01 2018-09-30 0001574774 us-gaap:EmployeeStockMember 2019-07-01 2019-09-30 0001574774 beat:PerformanceStockUnitsMember 2018-01-01 2018-09-30 0001574774 beat:PerformanceStockUnitsMember 2019-07-01 2019-09-30 0001574774 us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0001574774 beat:EmployeeDirectorAndConsultantStockOptionsMember 2018-12-31 beat:plan beat:segment xbrli:pure beat:customer iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________
FORM 10-Q
________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File Number 000-55039
http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=13183265&doc=10
BIOTELEMETRY, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
 
46-2568498
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
1000 Cedar Hollow Road
 
 
Malvern,
Pennsylvania
 
19355
(Address of principal executive offices)
 
(Zip Code)
(610) 729-7000
(Registrant’s Telephone Number, including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
BEAT
NASDAQ Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes    No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes    No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):
Large accelerated filer
Accelerated filer
Emerging growth company
Non-accelerated filer
Smaller reporting company
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes    No  
As of October 28, 2019, 33,991,107 shares of the registrant’s common stock were outstanding.
 




BIOTELEMETRY, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE PERIOD ENDED SEPTEMBER 30, 2019

TABLE OF CONTENTS
 
 
Page
PART I
 
Financial Statements (unaudited)
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
 
 
PART II
 
 
 
 
Unless the context otherwise indicates or requires, the terms “we,” “our,” “us,” “BioTelemetry” and the “Company,” as used in this Quarterly Report on Form 10-Q, refer to BioTelemetry, Inc. and its directly and indirectly owned subsidiaries as a combined entity, except where otherwise stated or where it is clear that the terms mean only BioTelemetry, Inc. exclusive of its subsidiaries. We do not use the ® or ™ symbol in each instance in which one of our registered or common law trademarks appears in this Quarterly Report on Form 10-Q, but this should not be construed as any indication that we will not assert our rights thereto to the fullest extent permissible under applicable law.

2



CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in our future. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Examples of forward-looking statements include statements we make regarding our ability to increase demand for our products and services, to leverage our Mobile Cardiac Outpatient Telemetry platform, to expand into new markets, to grow our market share, our expectations regarding revenue trends in our segments and the achievement of cost efficiencies through process improvement. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things:
our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business;
our ability to educate physicians and continue to obtain prescriptions for our products and services;
changes to insurance coverage and reimbursement levels by Medicare and commercial payors for our products and services;
our ability to attract and retain talented executive management and sales personnel;
the commercialization of new competitive products;
acceptance of our new products and services, such as our mobile cardiac telemetry (“MCT”) patch;
the outcome of our pending and ongoing incident investigation (as detailed in “Part I; Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this report), including our discovery of additional information relating to the incident and our customers’ and other stakeholders’ reactions to that additional information;
costs related the incident investigation and resulting liabilities;
our ability to obtain and maintain required regulatory approvals for our products, services and manufacturing facilities;
changes in governmental regulations and legislation;
adverse regulatory action;
our ability to obtain and maintain adequate protection of our intellectual property;
interruptions or delays in the telecommunications systems that we use;
our ability to successfully resolve outstanding legal proceedings; and
the other factors that are described in “Part I; Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2018, as well as the factors that are described

3



in “Part II; Item 1A. Risk Factors” of this Quarterly Report on Form 10-Q.
We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.


4

PART I — FINANCIAL INFORMATION


Item 1.  Financial Statements
BIOTELEMETRY, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and par value data)
(Unaudited)
September 30,
2019
 
December 31,
2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
61,573

 
$
80,889

Healthcare accounts receivable, net of allowance for doubtful accounts of $26,504 and $25,345, at September 30, 2019 and December 31, 2018, respectively
56,832

 
37,754

Other accounts receivable, net of allowance for doubtful accounts of $92 and $268, at September 30, 2019 and December 31, 2018, respectively
15,637

 
14,874

Inventory
6,389

 
7,323

Prepaid expenses and other current assets
9,712

 
5,820

Total current assets
150,143

 
146,660

Property and equipment, net of accumulated depreciation of $74,241 and $67,202, at September 30, 2019 and December 31, 2018, respectively
55,608

 
48,377

Intangible assets, net
133,593

 
129,653

Goodwill
304,101

 
238,814

Deferred tax assets
12,828

 
19,975

Other assets
19,891

 
3,322

Total assets
$
676,164

 
$
586,801

LIABILITIES AND EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
19,287

 
$
18,157

Accrued liabilities
28,487

 
24,689

Current portion of finance lease obligations
490

 
1,652

Current portion of long-term debt
12,813

 
5,125

Total current liabilities
61,077

 
49,623

Long-term portion of finance lease obligations
348

 
117

Long-term debt
182,825

 
193,424

Other long-term liabilities
71,007

 
33,152

Total liabilities
315,257

 
276,316

Stockholders’ equity:
 
 
 
Common stock—$0.001 par value as of September 30, 2019 and December 31, 2018; 200,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 33,991,107 and 33,406,364 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively
34

 
33

Paid-in capital
449,087

 
426,054

Accumulated other comprehensive (loss)/income
(624
)
 
256

Accumulated deficit
(87,590
)
 
(115,858
)
Total equity
360,907

 
310,485

Total liabilities and equity
$
676,164

 
$
586,801

See accompanying Notes to Consolidated Financial Statements.
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
(in thousands, except per share data)
2019
 
2018
 
2019
 
2018
Revenue
$
111,291


$
100,013

 
$
327,073

 
$
295,869

Cost of revenue
41,952

 
37,276

 
122,716

 
109,329

Gross profit
69,339

 
62,737

 
204,357

 
186,540

Operating expenses:
 
 
 
 
 
 
 
General and administrative
29,651

 
26,325

 
87,845

 
81,785

Sales and marketing
12,572

 
10,120

 
37,807

 
32,535

Bad debt expense
5,858

 
5,157

 
16,385

 
16,911

Research and development
3,661

 
2,429

 
10,526

 
8,451

Other charges
2,598

 
1,330

 
7,902

 
11,623

Total operating expenses
54,340

 
45,361

 
160,465

 
151,305

Income from operations
14,999

 
17,376

 
43,892

 
35,235

Other expense:
 
 
 
 
 
 
 
Interest expense
(2,338
)
 
(2,408
)
 
(7,358
)
 
(6,982
)
Loss on equity method investments
(65
)
 
(54
)
 
(251
)
 
(238
)
Other non-operating (expense)/income, net
(845
)
 
(194
)
 
(1,813
)
 
543

Total other expense, net
(3,248
)
 
(2,656
)
 
(9,422
)
 
(6,677
)
Income before income taxes
11,751

 
14,720

 
34,470

 
28,558

(Provision for)/benefit from income taxes
(3,468
)
 
1,281

 
(6,202
)
 
2,923

Net income
8,283

 
16,001

 
28,268

 
31,481

Net loss attributable to noncontrolling interest

 

 

 
(946
)
Net income attributable to BioTelemetry, Inc.
$
8,283

 
$
16,001

 
$
28,268

 
$
32,427

 
 
 
 
 
 
 
 
Net income per common share attributable to BioTelemetry, Inc.:
 
 
 
 
 
 
 
Basic
$
0.24

 
$
0.48

 
$
0.83

 
$
1.00

Diluted
$
0.23

 
$
0.45

 
$
0.78

 
$
0.91

Weighted average number of common shares outstanding:
 
 
 
 
 
 
 
Basic
33,908

 
33,003

 
33,885

 
32,488

Dilutive common stock equivalents
2,360

 
2,915

 
2,560

 
3,078

Diluted
36,268

 
35,918

 
36,445

 
35,566

See accompanying Notes to Consolidated Financial Statements.

5

BIOTELEMETRY, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)

 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
(in thousands)
2019
 
2018
 
2019
 
2018
Net income attributable to BioTelemetry, Inc.
$
8,283

 
$
16,001

 
$
28,268

 
$
32,427

Other comprehensive loss:
 
 
 
 
 
 
 
Foreign currency translation loss
(167
)
 
(27
)
 
(880
)
 
(194
)
Comprehensive income attributable to BioTelemetry, Inc.
$
8,116

 
$
15,974

 
$
27,388

 
$
32,233

See accompanying Notes to Consolidated Financial Statements.


6

BIOTELEMETRY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)


 
Nine Months Ended
 
September 30,
(in thousands)
2019
 
2018
OPERATING ACTIVITIES
 
 
 
Net income
$
28,268

 
$
31,481

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Bad debt expense
16,385

 
16,911

Depreciation and amortization
30,508

 
30,231

Stock-based compensation
9,662

 
6,278

Accretion of debt discount
932

 
932

Deferred income taxes
5,021

 
(4,149
)
Change in fair value of acquisition-related contingent consideration
(1,720
)
 
(700
)
Other non-cash items
(105
)
 
279

Changes in operating assets and liabilities:
 
 
 
Healthcare and other accounts receivable
(34,637
)
 
(28,826
)
Inventory
934

 
(3,454
)
Prepaid expenses and other assets
(3,493
)
 
1,932

Accounts payable
640

 
1,105

Accrued and other liabilities
207

 
(7,733
)
Net cash provided by operating activities
52,602

 
44,287

INVESTING ACTIVITIES
 
 
 
Acquisition of businesses, net of cash acquired
(44,766
)
 

Purchases of property and equipment and investment in internally developed software
(23,686
)
 
(17,498
)
Net cash used in investing activities
(68,452
)
 
(17,498
)
FINANCING ACTIVITIES
 
 
 
Proceeds related to the exercising of stock options and employee stock purchase plan
7,045

 
10,818

Payments of tax withholdings related to vesting of share-based awards
(4,955
)
 
(2,890
)
Principal payments on long-term debt
(3,844
)
 
(1,538
)
Principal payments on finance lease obligations
(1,735
)
 
(3,005
)
Acquisition of noncontrolling interests

 
(2,885
)
Net cash (used in)/provided by financing activities
(3,489
)
 
500

Effect of exchange rate changes on cash
23

 
(193
)
Net (decrease)/increase in cash and cash equivalents
(19,316
)
 
27,096

Cash and cash equivalents - beginning of period
80,889

 
36,022

Cash and cash equivalents - end of period
$
61,573

 
$
63,118

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
 
 
 
Non-cash purchases of property and equipment
$
1,721

 
$
1,056

Non-cash fair value of equity issued for acquisition of business
2,142

 

Non-cash fair value of equity issued for acquisition of noncontrolling interests

 
3,972

Cash paid for interest
6,301

 
5,830

Cash paid for taxes
$
617

 
$
1,120

See accompanying Notes to Consolidated Financial Statements.

7

BIOTELEMETRY, INC.
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited)




 
BioTelemetry, Inc. Equity
 
Common Stock
 
Paid-in Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated Deficit
 
Total Equity
(in thousands, except shares)
Shares
 
Amount
 
 
 
 
Balance at June 30, 2019
33,888,920

 
$
34

 
$
443,135

 
$
(457
)
 
$
(95,873
)
 
$
346,839

Share issuances related to stock compensation plans
102,187

 

 
2,316

 

 

 
2,316

Stock-based compensation

 

 
3,636

 

 

 
3,636

Currency translation adjustment

 

 

 
(167
)
 

 
(167
)
Net income

 

 

 

 
8,283

 
8,283

Balance at September 30, 2019
33,991,107

 
$
34

 
$
449,087

 
$
(624
)
 
$
(87,590
)
 
$
360,907



 
BioTelemetry, Inc. Equity
 
Common Stock
 
Paid-in Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated Deficit
 
Total Equity
(in thousands, except shares)
Shares
 
Amount
 
 
 
 
Balance at June 30, 2018
32,715,190

 
$
33

 
$
415,701

 
$
(281
)
 
$
(142,252
)
 
$
273,201

Share issuances related to stock compensation plans
496,868

 

 
4,985

 

 

 
4,985

Stock-based compensation

 

 
1,355

 

 

 
1,355

Currency translation adjustment

 

 

 
(27
)
 

 
(27
)
Net income

 

 

 

 
16,001

 
16,001

Balance at September 30, 2018
33,212,058

 
$
33

 
$
422,041

 
$
(308
)
 
$
(126,251
)
 
$
295,515




See accompanying Notes to Consolidated Financial Statements.

8

BIOTELEMETRY, INC.
CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited)




 
BioTelemetry, Inc. Equity
 
Common Stock
 
Paid-in Capital
 
Accumulated
Other
Comprehensive
Income/(Loss)
 
Accumulated Deficit
 
Total Equity
(in thousands, except shares)
Shares
 
Amount
 
 
 
 
Balance at December 31, 2018
33,406,364

 
$
33

 
$
426,054

 
$
256

 
$
(115,858
)
 
$
310,485

Share issuances related to stock compensation plans
599,161

 
1

 
7,044

 

 

 
7,045

Stock-based compensation

 

 
9,662

 

 

 
9,662

Shares withheld to cover taxes on vesting of share-based awards
(64,418
)
 

 
(4,955
)
 

 

 
(4,955
)
Issuance of stock related to business combination
50,000

 

 
2,142

 

 

 
2,142

Deferred purchase price consideration - equity portion

 

 
9,140

 

 

 
9,140

Currency translation adjustment

 

 

 
(880
)
 

 
(880
)
Net income

 

 

 

 
28,268

 
28,268

Balance at September 30, 2019
33,991,107

 
$
34

 
$
449,087

 
$
(624
)
 
$
(87,590
)
 
$
360,907



 
BioTelemetry, Inc. Equity
 
 
 
 
 
Common Stock
 
Paid-in Capital
 
Accumulated
Other
Comprehensive
Loss
 
Accumulated Deficit
 
Noncontrolling Interest
 
Total Equity
(in thousands, except shares)
Shares
 
Amount
 
 
 
 
 
Balance at December 31, 2017
31,906,195

 
$
32

 
$
409,517

 
$
(114
)
 
$
(158,678
)
 
$
(1,054
)
 
$
249,703

Share issuances related to stock compensation plans
1,332,254

 
1

 
11,136

 

 

 

 
11,137

Stock-based compensation

 

 
6,278

 

 

 

 
6,278

Shares withheld to cover taxes on vesting of share-based awards
(85,177
)
 

 
(2,890
)
 

 

 

 
(2,890
)
Acquisition of noncontrolling interest
58,786

 

 
(2,000
)
 

 

 
2,000

 

Currency translation adjustment

 

 

 
(194
)
 

 

 
(194
)
Net income/(loss)

 

 

 

 
32,427

 
(946
)
 
31,481

Balance at September 30, 2018
33,212,058

 
$
33

 
$
422,041

 
$
(308
)
 
$
(126,251
)
 
$

 
$
295,515




See accompanying Notes to Consolidated Financial Statements.

9

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)



1. Summary of Significant Accounting Policies
a) Principles of Consolidation & Reclassifications
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information, the instructions to Form 10-Q, and Rule 10-01 of Regulation S-X and include the accounts of BioTelemetry, Inc. and its controlled subsidiaries (“BioTelemetry,” the “Company,” “we,” “our” or “us”). In the opinion of management, all adjustments (which are of a normal and recurring nature) considered necessary to present fairly the financial position, the results of operations, and statements of comprehensive income, cash flows, and equity for the interim periods ended September 30, 2019 and 2018 have been included. All intercompany transactions and balances have been eliminated in consolidation. The results of operations for any interim period are not indicative of the results of the full year. Certain information and footnote disclosures normally included in consolidated financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Certain reclassifications have been made to prior period statements to conform to the current period presentation. These consist of combining our non-cash depreciation and amortization expenses into one line on our consolidated statements of cash flows and separating the non-cash operating item of change in fair value of acquistion-related contingent consideration from other non-cash items on our consolidated statements of cash flows. These reclassifications had no impact on previously reported working capital, consolidated results of operations, cash flows or accumulated deficit.
b) Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.
c) Fair Value of Financial Instruments
Fair value is defined as the exit price, the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as defined below. Observable inputs are inputs a market participant would use in valuing an asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our own assumptions about the factors a market participant would use in valuing an asset or liability developed using the best information available in the circumstances. The classification of an asset’s or liability’s level within the fair value hierarchy is determined based on the lowest level input that is significant to the fair value measurement.
Level 1 -
Quoted prices in active markets for an identical asset or liability.
Level 2 -
Inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability.

10

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


Level 3 -
Inputs that are unobservable for the asset or liability, based on our own assumptions about the assumptions a market participant would use in pricing the asset or liability.
Our financial instruments consist primarily of cash and cash equivalents, Healthcare accounts receivable, other accounts receivable, accounts payable, acquisition-related contingent consideration, short-term debt and long-term debt. With the exception of acquisition-related contingent consideration and long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1).
Our long-term debt (classified as Level 2) is measured using market prices for similar instruments, inputs such as the borrowing rates currently available, benchmark yields, actual trade data, broker/dealer quotes and other similar data obtained from quoted market prices or independent pricing vendors.
The fair value of acquisition-related contingent consideration (classified as Level 3) is measured on a recurring basis using a Monte Carlo simulation. This model uses assumptions, including estimated projected revenues, estimated stock price volatility in future periods, estimated discount rates and discounts for the lack of marketability of common stock. In addition to the recurring fair value measurements, the fair value of certain assets acquired and liabilities assumed in connection with a business combination are recorded at fair value, primarily using a discounted cash flow model (classified as Level 3). This valuation technique requires us to make certain assumptions, including future operating performance, cash flows and revenue growth rates, royalty rates and other such variables, which are discounted to present value using a discount rate that reflects the risk factors associated with future cash flow, the characteristics of the assets acquired and liabilities assumed and the experience of the acquired business. Non-financial assets such as goodwill, intangible assets, and property and equipment are subsequently measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment is recognized. We assess the impairment of goodwill and intangible assets annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable.
d) Accounts Receivable and Allowance for Doubtful Accounts
Healthcare accounts receivable is recorded at the time Healthcare segment revenue is recognized and is presented on the consolidated balance sheet net of an allowance for doubtful accounts. For our contracted payors, we determine revenue based on negotiated prices for the services provided. Based on our history, we have experience collecting substantially all of the negotiated contracted rates and are therefore not providing an implicit price concession. As a result, an allowance for doubtful accounts is recorded based on historical collection trends to account for the risk of patient default. Because of continuing changes in the health care industry and third-party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows.
Other accounts receivable is related to the Research segment and Corporate and Other category and is recorded at the time revenue is recognized, when products are shipped or services are performed. We estimate an allowance for doubtful accounts on a specific account basis and consider several factors in our analysis, including customer specific information.
We write off receivables when the likelihood for collection is remote, we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis.

11

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


e) Acquisition-Related Contingent Consideration
Acquisition-related contingent consideration is our obligation, arising from a business combination, to transfer additional assets and/or equity interests to the seller if certain future events occur or conditions are met. The fair value of the contingency is estimated as of the acquisition date using certain unobservable inputs (and therefore classified as Level 3 in the fair value hierarchy) and is recorded as a liability. We re-measure the estimated fair value of acquisition-related contingent consideration classified as a liability at each reporting date. Adjustments subsequent to the acquisition measurement period are recorded in other charges in the consolidated statements of operations. Changes to the inputs used in the measurement of acquisition-related contingent consideration include, but are not limited to: changes in the assumptions regarding probabilities of successful achievement of future events or conditions; estimated revenue projections; discounts for lack of marketability of our common stock; estimated stock price volatility; and the discount rate used to estimate the fair value of the liability. Acquisition-related contingent consideration may change significantly as our inputs and assumptions noted above evolve and additional data is obtained. The inputs and assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in different fair value estimates that may have a material impact on our results from operations and financial position.
f) Concentrations of Credit Risk
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, Healthcare accounts receivable and other accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased.
At September 30, 2019 and December 31, 2018, one payor, Medicare, accounted for 21% and 15%, respectively, of our gross accounts receivable.
g) Noncontrolling Interest
The consolidated financial statements reflect the application of Accounting Standards Codification (“ASC”) 810 - Consolidations, which establishes accounting and reporting standards that require: (i) the ownership interest in subsidiaries held by parties other than the parent to be clearly identified and presented in the consolidated balance sheet within stockholders’ equity but separate from the parent’s equity; (ii) the amount of consolidated net income/(loss) attributable to the parent and the noncontrolling interest to be clearly identified and presented in the consolidated statements of operations; and (iii) changes in a parent’s ownership interest while the parent retains its controlling financial interest in its subsidiary to be accounted for consistently.
h) Leases
We lease our administrative and service facilities, as well as certain office equipment, monitoring devices and information technology equipment under arrangements classified as leases under ASC 842 - Leases (“ASC 842”). We adopted ASC 842 using the optional modified retrospective transition method as of January 1, 2019, therefore prior period amounts are not restated.

12

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


We recognize right-of-use (“ROU”) assets at the inception of the arrangement as the present value of the lease payments plus our initial direct costs (if any), less any lease incentives. The corresponding liability is computed as the present value of the lease payments at inception. Assets are classified as either operating or finance ROU assets according to the classification criteria in ASC 842. Upon the adoption of ASC 842, we elected the transition practical expedients to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to adoption of ASC 842 and to not separate lease and non-lease components where we are the lessor when the requisite criteria is met to be treated as such. The present value of the lease payments is computed using the rate implicit in the lease (if known) or our incremental borrowing rate.
Operating lease costs are charged to operations on a straight-line basis over the lease term. Interest charged on the finance lease liabilities is charged to interest expense, while the amortization of the finance lease ROU assets is also charged to operations on a straight-line basis.
Under our policy, we do not record an ROU asset or corresponding liability for arrangements where the initial lease term is one year or less, or when the ROU asset at inception is deemed immaterial. Those leases are expensed on a straight-line basis over the term of the lease.
Effective January 1, 2019, for our operating leases, we record the ROU assets as a component of other assets, the current lease liability as a component of accrued liabilities, and the long-term lease liability as a component of other long-term liabilities on our consolidated balance sheet. For our finance leases, we record the ROU asset and the accumulated amortization for the finance ROU asset as a component of property and equipment, net, with the current and long-term portions of the finance lease obligations as separate lines within our consolidated balance sheet. We amortize the finance ROU assets over the shorter of the remaining lease term or the estimated life of the asset.
i) Stock-Based Compensation
ASC 718 - Compensation - Stock Compensation (“ASC 718”), addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for: (i) equity instruments of the enterprise or (ii) liabilities that are based on the fair value of the enterprise’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measure the cost of equity-based service awards issued to employees, such as stock options and restricted stock units (“RSUs”), based on the grant-date fair value of the award and recognize the cost of such awards over the requisite service period (generally, the vesting period of the award). The compensation expense associated with performance stock units (“PSUs”) is recognized ratably over the period between when the performance conditions are deemed probable of achievement and when the awards are vested. Performance stock options (“PSOs”) are valued and stock-based compensation expense is recorded once the performance conditions of the outstanding PSOs have achieved probability. Prior to July 1, 2018, we accounted for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees; see “m) Recent Accounting Pronouncements; Accounting Pronouncements Recently Adopted” for further details related to our adoption of Accounting Standards Update (“ASU”) 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, during the three months ended June 30, 2018 and our current accounting for equity awards issued to non-employees.
We have historically recorded stock-based compensation expense based on the number of stock options or RSUs we expect to vest using our historical forfeiture experience and we periodically update

13

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


those forfeiture rates to apply to new grants. While we early adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting during the year ended December 31, 2016, we have elected to continue to estimate forfeitures under the true-up provision of ASC 718. We record additional expense if the actual forfeiture rate is lower than estimated and record a recovery of prior expense if the actual forfeiture rate is higher than estimated.
We estimate the fair value of our stock options using the Black‑Scholes option valuation model. The Black‑Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of our stock and the expected term of the award. We base our estimates of expected volatility on the historical average of our stock price. The expected term represents the period of time that share‑based awards granted are expected to be outstanding. Other assumptions used in the Black‑Scholes option valuation model include the risk‑free interest rate and expected dividend yield. The risk‑free interest rate for periods pertaining to the expected term of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. We have never paid, and do not expect to pay, dividends in the foreseeable future.
We estimate the fair value of our PSUs using a Monte Carlo simulation. This model uses assumptions, including the risk free interest rate, expected volatility of our stock price and those of the performance group, dividends of the performance group members and expected life of the awards. As noted above, we continue to estimate forfeitures under the true-up provision of ASC 718. If it is deemed probable that the PSU performance targets will be met, compensation expense is recorded for these awards ratably over the requisite service period. The PSUs are forfeited to the extent the performance criteria are not met within the service period.
j) Income Taxes
We account for income taxes under the liability method, as described in ASC 740 - Income Taxes (“ASC 740”). Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and consolidated financial statement reporting bases of assets and liabilities. When we determine that we will not be able to realize our deferred tax assets, we adjust the carrying value of the deferred tax asset through the valuation allowance.
Under ASC 740, the effects of changes in tax rates and tax laws on deferred tax balances are recognized in the period in which the new legislation is enacted. The total effect of tax law changes on deferred tax balances is recorded as a component of income tax expense.
We record unrecognized tax benefits in accordance with ASC 740 on the basis of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.
k) Net Income/(Loss) Per Share
We compute net income/(loss) per share in accordance with ASC 260 - Earnings Per Share. Basic net income/(loss) per share is computed by dividing net income/(loss) by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by giving effect to all potential dilutive common stock equivalents, including stock options, RSUs, PSOs and PSUs, using

14

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


the treasury stock method and shares expected to be issued in connection with acquisition-related contingent consideration arrangements when dilutive.
Certain stock options, which are priced higher than the average market price of our shares for the periods ended September 30, 2019 and September 30, 2018 would be anti-dilutive and therefore have been excluded from the weighted average shares used in computing diluted net income per share. These options could become dilutive in future periods. Similarly, certain recently granted RSUs and PSUs are also excluded using the treasury stock method as their impact would be anti-dilutive. The dilutive effect of weighted average shares outstanding excludes approximately 1.0 million and 0.4 million shares for the three and nine month periods ended September 30, 2019, respectively, and excludes approximately 0.1 million and 0.5 million shares for the three and nine month periods ended September 30, 2018, respectively, as their effect would have been anti-dilutive on our net income per share.
l) Segment Information
ASC 280 - Segment Reporting, establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance.
We report our business under two segments: Healthcare and Research. The Healthcare segment is focused on remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders and to monitor the functionality of implantable cardiac devices. We offer cardiologists, electrophysiologists, neurologists and primary care physicians a full spectrum of solutions, which provides them with a single source of cardiac monitoring services. The Research segment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. Included in the Corporate and Other category is the manufacturing, testing and marketing of cardiac and blood glucose monitoring devices to medical companies, clinics and hospitals and corporate overhead and other items not allocated to any of our reportable segments.
m) Recent Accounting Pronouncements
Accounting Pronouncements Recently Adopted
In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The updated guidance also requires an entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. Historically, our implementation costs incurred in hosting service contracts have not been material. We early adopted this standard effective April 1, 2019 on a prospective basis. Upon adoption, our cloud computing implementation costs are deferred and recorded as a component of technology within intangible assets in our consolidated balance sheet and amortized to selling, general and administrative costs over the life of the service arrangement on our statement of operations. This update did not have a material impact on our financial position, results of operations or disclosures.

15

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


In August 2018, the U.S. Securities and Exchange Commission (“SEC”) adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. Additionally, the amendments expanded the disclosure requirements on the consolidated statements of equity for interim consolidated financial statements. Under the amendments, a summary of changes in each caption of stockholders’ equity presented in the consolidated balance sheets must be provided in a note or separate statement. The consolidated statements of equity should present a reconciliation of the beginning balance to the ending balance of each period for which the consolidated statement of comprehensive income is required to be filed. This final rule was effective in the fourth quarter of 2018. The SEC provided relief on the effective date until the first quarter of 2019, and we adopted this rule in the first quarter of 2019.
In June 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). This update expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). The amendments in ASU 2018-07 are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption was permitted. We adopted this standard on July 1, 2018, effective January 1, 2018, and this standard did not have a material impact on our financial position, results of operations or disclosures.
In February 2016, the FASB issued ASU 2016-02, Leases. This standard, along with several subsequent updates, requires lessees to recognize most leases on their balance sheet, make selected changes to lessor accounting and disclose additional key information about leases. We adopted these updates on January 1, 2019, using the optional modified retrospective transition method and utilizing practical expedients available. The adoption of the new standard resulted in the recording, as of January 1, 2019, of additional ROU assets of $22.7 million as a component of other assets, current ROU liabilities of $6.2 million as a component of accrued liabilities and long-term ROU liabilities of $16.5 million, all of which relate to our operating leases. The adoption of the new standard did not materially impact our consolidated results of operations and had no impact on our cash flows.
Accounting Pronouncements Not Yet Adopted
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). This update eliminates certain disclosures related to transfers and valuation processes, clarifies the requirement for measurement uncertainty disclosures, and requires additional disclosures for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. We are in the process of evaluating the impact of this update on our consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses. This update, along with subsequent amendments, introduces the current expected credit loss model, which will require

16

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, upon initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update will be effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years, with early adoption permitted. We are in the process of evaluating the impact of this update on our consolidated financial statements and related disclosures.


2. Revenue Recognition
We adopted ASC 606 on January 1, 2018, which requires revenue recognized to represent the transfer of promised goods or services to customers at an amount that reflects the consideration that a company expects to receive in exchange for those goods or services.
We utilized the modified retrospective method for adoption, allowing us to not retrospectively adjust prior periods. We applied the modified retrospective method only to contracts that were not complete at January 1, 2018 and accounted for the aggregate effect of any contract modifications upon adoption. No cumulative adjustment to retained earnings was recorded.
Disaggregation of Revenue
We disaggregate revenue from contracts with customers by payor type and major service line. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, amount, timing and uncertainty of our revenue streams. Disaggregated revenue by payor type and major service line for the three and nine months ended September 30, 2019 and 2018 were as follows:
 
Three Months Ended September 30, 2019
 
Reporting Segment
 
 
 
Total Consolidated
(in thousands)
Healthcare
 
Research
 
Other
 
Payor/Service Line
 
 
 
 
 
 
 
Remote cardiac monitoring services - Medicare
$
39,537

 
$

 
$

 
$
39,537

Remote cardiac monitoring services - commercial payors
54,336

 

 

 
54,336

Clinical trial support and related services

 
14,236

 

 
14,236

Technology devices, consumables and related services

 

 
3,182

 
3,182

Total
$
93,873

 
$
14,236

 
$
3,182

 
$
111,291



17

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


 
Three Months Ended September 30, 2018
 
Reporting Segment
 
 
 
Total Consolidated
(in thousands)
Healthcare
 
Research
 
Other
 
Payor/Service Line
 
 
 
 
 
 
 
Remote cardiac monitoring services - Medicare
$
34,638

 
$

 
$

 
$
34,638

Remote cardiac monitoring services - commercial payors
49,558

 

 

 
49,558

Clinical trial support and related services

 
13,464

 

 
13,464

Technology devices, consumables and related services

 

 
2,353

 
2,353

Total
$
84,196

 
$
13,464

 
$
2,353

 
$
100,013


 
Nine Months Ended September 30, 2019
 
Reporting Segment
 
 
 
Total Consolidated
(in thousands)
Healthcare
 
Research
 
Other
 
Payor/Service Line
 
 
 
 
 
 
 
Remote cardiac monitoring services - Medicare
$
114,573

 
$

 
$

 
$
114,573

Remote cardiac monitoring services - commercial payors
162,313

 

 

 
162,313

Clinical trial support and related services

 
41,079

 

 
41,079

Technology devices, consumables and related services

 

 
9,108

 
9,108

Total
$
276,886

 
$
41,079

 
$
9,108

 
$
327,073

 
Nine Months Ended September 30, 2018
 
Reporting Segment
 
 
 
Total Consolidated
(in thousands)
Healthcare
 
Research
 
Other
 
Payor/Service Line
 
 
 
 
 
 
 
Remote cardiac monitoring services - Medicare
$
101,452

 
$

 
$

 
$
101,452

Remote cardiac monitoring services - commercial payors
150,018

 

 

 
150,018

Clinical trial support and related services

 
37,254

 

 
37,254

Technology devices, consumables and related services

 

 
7,145

 
7,145

Total
$
251,470

 
$
37,254

 
$
7,145

 
$
295,869


Remote Cardiac Monitoring Services Revenue (Healthcare segment)
Healthcare segment revenue is generated by remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders and to monitor the functionality of implantable cardiac devices. We offer cardiologists, electrophysiologists, neurologists and primary care physicians a full spectrum of solutions, which provides them with a single source of cardiac monitoring services.
Performance obligations are determined based on the nature of the services provided. With our remote cardiac monitoring services, the patient receives the benefits of the service over time, resulting in revenue recognition over time based on the output method. We believe that this method provides an accurate depiction of the transfer of value over the term of the performance obligation because the level of effort in providing these services is consistent during the service period.

18

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


A summary of the payment arrangements with payors is as follows:
Contracted payors (including Medicare): We determine the transaction price based on negotiated prices for services provided, on a case rate basis, as provided for under the relevant Current Procedural Terminology (“CPT”) codes.
Non-contracted payors: Non-contracted commercial and government insurance carriers often reimburse out-of-network rates provided for under the relevant CPT codes on a case rate basis. Our transaction price includes implicit price concessions based on our historical collection experience for our non-contracted patients.
We are utilizing the portfolio approach practical expedient in ASC 606 for our patient contracts in the Healthcare segment. We account for the contracts within each portfolio as a collective group, rather than individual contracts. Based on our history with these portfolios and the similar nature and characteristics of the patients within each portfolio, we have concluded that the financial statement effects are not materially different than if accounting for revenue on a contract-by-contract basis.
For the contracted portfolio, we have historical experience of collecting substantially all of the negotiated contractual rates and determined at contract inception that these customers have the intention and ability to pay the promised consideration. As such, we are not providing an implicit price concession but, rather, have chosen to accept the risk of default, and adjustments to the transaction price are recorded as bad debt expense.
For our non-contracted portfolio, we are providing an implicit price concession because we do not have a contract with the underlying payor, the result of which requires us to estimate our transaction price based on historical cash collections utilizing the expected value method. Subsequent adjustments to the transaction price are recorded as an adjustment to Healthcare segment revenue and not as bad debt expense.
We have not made any significant changes to judgments in applying ASC 606 to the Healthcare segment during the three and nine months ended September 30, 2019.
Clinical Trial Support and Related Services Revenue (Research segment)
Research segment revenue is generated by providing centralized core laboratory services, including cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials. These amounts are due from pharmaceutical companies and contract research organizations. We bill our customers on a fee for service basis. Under a typical contract, some customers pay us a portion of our fee upon contract execution as an upfront refundable deposit. Upfront deposits are deferred and then recognized as the services are performed. If a contract is canceled prior to service being provided, the upfront deposit is refunded.
Performance obligations are determined based on the nature of the services provided by us. Our core laboratory services are provided over time as the customer receives benefits resulting in revenue recognition over the term of the contract. Our research customer contracts have legally enforceable terms that are predominately thirty days due to termination for convenience clauses, which are held by the customer with no significant penalty. Given the short-term nature of these contracts and the structure of our billing practices, our billing practices approximate our performance if measured by an output method, where each output is an individual occurrence of each performance obligation. Accordingly, we utilize the invoice

19

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


practical expedient as defined in ASC 606, resulting in recognition of revenue in the amount that we have the right to invoice.
We have not made any significant changes to judgments in applying ASC 606 to the Research segment during the three and nine months ended September 30, 2019.
Other Revenue (Other category)
Our Other category revenue is primarily derived from the sale of non-invasive cardiac monitors to healthcare companies, wireless blood glucose meters and test strips to wholesale distributors of diabetes supplies and diabetic patients, as well as product repairs. Performance obligations are primarily the sale of devices, related goods and repairs provided by us. These contracts transfer control to a customer at a point in time based on the transfer of title for the underlying good or service. We provide standard warranty provisions.
We determine the transaction price based on fixed consideration in our contractual agreements with our customers and allocate the transaction price to each performance obligation based on the relative stand-alone selling price. We determine the relative stand-alone selling price utilizing our observable prices for the sale of the underlying goods.
We have not made any significant changes to judgments in applying ASC 606 to the Other category during the three and nine months ended September 30, 2019.
Contract Assets and Contract Liabilities
ASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under the contract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g. receivable), before the entity transfers a good or service to the customer.
As of September 30, 2019 and December 31, 2018, we had contract assets of $9.8 million and $2.1 million, respectively, due to cardiac monitoring services.  Our contract assets are included as a component of Healthcare accounts receivable on our consolidated balance sheets.
As of September 30, 2019 and December 31, 2018, we had contract liabilities of $1.7 million and $3.1 million, respectively, primarily related to the Research segment where customers paid upfront deposits upon contract execution for future services to be performed by us. If the contract is canceled, these upfront deposits are refundable if service was not yet provided. Our contract liabilities are now included as a component of accrued liabilities on our consolidated balance sheets.
For the three months ended September 30, 2019, the amount recognized as revenue from the contract liabilities balance at June 30, 2019 was $0.6 million, while for the nine months ended September 30, 2019, the amount recognized as revenue from the contract liabilities balance as of December 31, 2018 was $1.9 million. Similarly, for the three months ended September 30, 2018, the amount recognized as revenue from the contract liabilities balance at June 30, 2018 was $1.0 million, while for the nine months ended September 30, 2018, the amount recognized as revenue from the contract liabilities balance as of

20

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


December 31, 2017 was $2.6 million. No significant changes or impairment losses occurred to contract balances during the nine months ended September 30, 2019.
Practical Expedient Elections
We have elected the following practical expedients in applying ASC 606 across all reportable segments unless otherwise noted below.
Unsatisfied Performance Obligations: Because all of our performance obligations relate to contracts with a duration of less than one year, we have elected to apply the optional exemption provided in ASC 606 and, therefore, are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.
Contract Costs: All incremental customer contract acquisition costs are expensed as they are incurred as the amortization period of the asset that we otherwise would have recognized is one year or less in duration.
Significant Financing Component: We do not adjust the promised amount of consideration for the effects of a significant financing component as we expect, at contract inception, that the period between when we transfer a promised good or service to a customer and when the customer pays for that good or service will be one year or less.
Sales Tax Exclusion from the Transaction Price: We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by us from the customer.
Shipping and Handling Activities: For our Other category revenue, we account for shipping and handling activities we perform after a customer obtains control of the good as activities to fulfill the promise to transfer the good.


3. Acquisitions
ADEA Medical AB
During the second quarter of 2019, we acquired all of the remaining outstanding equity of ADEA Medical AB, now known as BioTel Europe AB (“ADEA” or “BioTel Europe”), a limited company incorporated and registered under the laws of Sweden. BioTel Europe provides cardiac monitoring in northern Europe.
Pursuant to the acquisition agreement, we agreed to issue the owners of ADEA 50,000 shares of our common stock, with a fair value of approximately $2.1 million, as well as to pay approximately $0.2 million in cash. The shares are restricted, with the restrictions related to 10,000 shares expiring in the fourth quarter of 2019, and the restrictions on the remaining 40,000 shares expiring in the second quarter of 2022, and the shares are also available to satisfy indemnification obligations.
Prior to the second quarter of 2019, we accounted for our 23.8% stake in ADEA as an equity method investment. We accounted for the acquisition of the remaining equity of ADEA as a step acquisition, which required us to re-measure our previous ownership interest to fair value prior to application of purchase

21

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


accounting, and we recognized the immaterial difference between the fair value and the carrying value of the equity method investment at that time. The total purchase price of ADEA was $3.3 million, primarily consisting of the equity and cash consideration paid in the second quarter of 2019, plus the amounts paid for our initial investment in ADEA in 2018. We then allocated this purchase price to the assets acquired and liabilities assumed. The acquired net assets consisted primarily of customer relationships and non-compete agreements. The excess of the fair value of the purchase price over the fair value of the net assets acquired has been recognized as goodwill, which represents the expected future benefits arising from the assembled workforce and other synergies attributable to cost savings opportunities. We have recognized $2.6 million of goodwill as a result of the acquisition, all of which has been assigned to the Healthcare segment. None of this goodwill will be deductible for tax purposes.
We finalized our fair value estimates related to the BioTel Europe acquisition during the three months ended September 30, 2019. There were no changes to the total purchase price, and the measurement period adjustment related to deferred income taxes during the three months ended September 30, 2019 was not material.
We do not consider this acquisition to be significant to our results of operations. The transaction costs related to this acquisition and revenues and results of operations of BioTel Europe prior to our acquisition were all immaterial.
Geneva Healthcare, Inc.
On March 1, 2019, we acquired Geneva Healthcare, Inc., now known as Geneva Healthcare, LLC (“Geneva”), for cash consideration in the amount of $45.9 million. In addition, pursuant to the terms of the Agreement and Plan of Merger, dated January 25, 2019, by and among Geneva, BioTelemetry, Inc., Tyersall Merger Sub, Inc., and the Securityholders’ Representative (the “Geneva Agreement”), on the third anniversary date of the closing date, the Securityholders (as defined in the Geneva Agreement) are eligible to receive additional consideration in the form of cash payments, as well as shares of BioTelemetry common stock, with a total estimated present value of $32.0 million as of the March 1, 2019 acquisition date, for a total aggregate purchase price of $77.9 million. Concurrent with the closing of the acquisition, the Securityholders made elections as to the percentage mix of their total additional consideration to be settled in cash or common stock.
The estimated additional consideration of $32.0 million, as of the March 1, 2019 acquisition date, consists of the following:
The Securityholders will, subject to potential deductions pursuant to the Geneva Agreement, receive additional consideration of $20.0 million, a total of $11.1 million of which will be paid in cash, and the remaining value will be settled in shares. We will issue a total of 131,594 shares of our common stock to settle the share-related portion of the obligation, based on the elections made by the Securityholders and the formulas within the Geneva Agreement.
The estimated present value of the future cash payment of $11.1 million, which totals $9.7 million as of the acquisition date, as well as the estimated fair value of our common stock of $9.1 million, has been included within the purchase price for Geneva. The estimated present value of the future cash payment is recorded as a component of other long-term liabilities and will be accreted to its redemption value through interest expense through the payment date. The estimated fair value of the 131,594 shares our common stock has been recorded within paid-in-capital.

22

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


The Securityholders will also be eligible to receive additional consideration, in the form of both cash and shares, based on a predetermined formula that is driven by the future revenues of Geneva and does not have a predetermined limit. The total estimated acquisition-related contingent consideration as of the March 1, 2019 acquisition date is $13.2 million, which is also included in the purchase price of Geneva. The $13.2 million is recorded within other long-term liabilities and will be marked to market through earnings on a quarterly basis throughout the earn-out period. The equity portion of the acquisition-related contingent consideration requires liability classification and mark-to-market accounting pursuant to the provisions of ASC 815 - Derivatives and Hedging.
We acquired Geneva as part of our business strategy to go deeper and wider into the cardiac monitoring market. Geneva has developed an innovative proprietary cloud-based platform that aggregates data from the leading cardiac device manufacturers, enabling the Company to remotely monitor a physician’s patients with implantable cardiac devices such as pacemakers, defibrillators and loop recorders. Geneva’s platform provides physicians a single portal to order patient monitoring, review monitoring results and request routine device checks, helping drive significant in-office efficiencies and patient compliance. We plan to merge this functionality with that of the Healthcare segment user interface, which we believe will drive greater workflow and data management efficiencies to the clients we serve.
We accounted for the transaction as a business combination, and as such, all assets acquired and liabilities assumed were recorded at their estimated fair values. The excess of the fair value of the purchase price over the fair value of the net assets acquired has been recognized as goodwill, which represents the expected future benefits arising from the assembled workforce and other synergies attributable to cost savings opportunities. We have recognized $62.8 million of goodwill as a result of the acquisition, all of which has been assigned to the Healthcare segment. None of this goodwill will be deductible for tax purposes.
The amounts in the table below represent our final fair value estimates related to the Geneva acquisition as of March 1, 2019. Measurement period adjustments recorded during the second quarter of 2019 consisted primarily of decreasing additional consideration by $2.2 million. We finalized our fair value estimates related to the Geneva acquisition during the three months ended September 30, 2019, during which time there were no material measurement period adjustments recorded.

23

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


(in thousands, except years)
Amount
 
Weighted
Average Life
(Years)
Fair value of assets acquired:
 
 
 
Cash and cash equivalents
$
1,376

 
 
Healthcare accounts receivable
1,500

 
 
Prepaid expenses and other current assets
234

 
 
Identifiable intangible assets:
 
 
 
Customer relationships
3,500

 
12
Technology
8,900

 
7
Trade names
2,500

 
15
Total identifiable intangible assets
14,900

 
 
Total assets acquired
18,010

 
 
Fair value of liabilities assumed:
 
 
 
Accounts payable
215

 
 
Accrued liabilities
872

 
 
Deferred tax liabilities
1,879

 
 
Total liabilities assumed
2,966

 
 
 
 
 
 
Total identifiable net assets
15,044

 
 
Goodwill
62,836

 
 
Net assets acquired
$
77,880

 
 

We have incurred $1.4 million of acquisition related costs associated with Geneva for the nine months ended September 30, 2019. The costs were included in other charges in our consolidated statements of income. The revenues and income of Geneva for periods prior to our acquisition were immaterial to our consolidated operating results.
ActiveCare
On October 2, 2018, we acquired, through our subsidiary Telcare Medical Supply, LLC, certain assets of ActiveCare, Inc. (“ActiveCare”) for $3.8 million in cash. The purchase price also includes a potential earn-out payment of $2.0 million, which is contingent on the achievement of certain revenue targets by November 1, 2020. We accounted for the transaction as a business combination, and as such, all assets acquired were recorded at their estimated fair values. The excess of the fair value of the purchase price over the fair value of the net assets acquired has been recognized as goodwill, has been assigned to the Corporate and Other category and will be deductible for tax purposes. The acquired net assets primarily consisted of customer relationships and software developed by ActiveCare. The earn-out was assigned no value as of the acquisition date as it was and is currently not probable of achievement. We finalized our fair value estimates related to the ActiveCare acquisition during the three months ended March 31, 2019, and there were no changes to the amounts initially recorded. The transaction costs related to this acquisition and revenues and net income of ActiveCare prior to our acquisition were all immaterial.



24

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


4. Inventory
Inventory consists of the following:
(in thousands)
September 30,
2019
 
December 31,
2018
Raw materials and supplies
$
4,421

 
$
3,667

Finished goods
1,968

 
3,656

Total inventory
$
6,389

 
$
7,323




5. Fair Value Measurements
We have determined that our long-term debt, classified as Level 2, has a fair value consistent with its carrying value, net of debt discount and deferred charges, of $195.6 million and $198.5 million as of September 30, 2019 and December 31, 2018, respectively.
Acquisition-related contingent consideration represents our contingent payment obligations related to our acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of acquisition-related contingent consideration uses assumptions we believe would be made by a market participant. We assess these estimates on an ongoing basis as additional data impacting the assumptions is obtained. The balance of the fair value of acquisition-related contingent consideration is recognized within other long-term liabilities on our consolidated balance sheet as of September 30, 2019. Changes in the fair value of the acquisition-related contingent consideration, after the final determination as of the acquistion date, resulting from changes in the variables used to compute the fair value, are recorded in other charges in the consolidated statements of operations.
The following table provides a reconciliation of the beginning and ending balances of acquisition-related contingent consideration:
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
(in thousands)
2019
 
2018
 
2019
 
2018
Beginning balance
$
11,360

 
$

 
$

 
$
700

Acquisition-related contingent consideration

 

 
13,170

 

Changes in fair value of acquisition-related contingent consideration
90

 

 
(1,720
)
 
(700
)
Ending balance
$
11,450

 
$

 
$
11,450

 
$


In conjunction with the Geneva acquisition, we recognized $13.2 million of acquisition-related contingent consideration on March 1, 2019 as a component of other long-term liabilities, as the contingency will be finalized after the third anniversary of the closing date. There was no value assigned to the acquisition-related contingent consideration related to the ActiveCare acquisition as the achievement of the contingency was not probable as of September 30, 2019.
The estimated fair value of the acquisition-related contingent consideration related to the Geneva acquisition was determined using a Monte Carlo simulation, that considered numerous variables, including

25

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


estimates for projected revenues, future stock price, discount rates and discounts for lack of marketability of common stock. These estimates are subject to a significant level of judgment.
During the nine months ended September 30, 2019, excluding the measurement period adjustments, the acquisition-related contingent consideration related to the Geneva acquisition declined $1.7 million primarily due to changes in estimates associated with our future stock price. During the nine months ended September 30, 2018, the fair values of the acquisition-related contingent consideration related to our 2016 Telcare acquisition decreased $0.7 million, as it was no longer probable that any of the contingencies would be met.


6. Goodwill and Intangible Assets
Goodwill was recognized at the time of our acquisitions. The following table presents the carrying amount of goodwill allocated to our reportable segments, as well as the changes to goodwill during the nine months ended September 30, 2019:
 
Reporting Segment
 
Corporate and Other
 
 
(in thousands)
Healthcare
 
Research
 
 
Total
Balance at December 31, 2018
$
213,507

 
$
16,293

 
$
9,014

 
$
238,814

Goodwill acquired
65,408

 

 

 
65,408

Currency translation
(121
)
 

 

 
(121
)
Balance at September 30, 2019
$
278,794

 
$
16,293

 
$
9,014

 
$
304,101


The goodwill acquired in the Healthcare segment is related to the Geneva and BioTel Europe acquisitions. Refer to “Note 3. Acquisitions” for details.

26

BIOTELEMETRY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
(Unaudited)


The gross carrying amounts and accumulated amortization of our intangible assets are as follows:
(in thousands, except years)
Weighted
Average Life
(Years)
 
September 30,
2019
 
December 31,
2018
Gross Carrying Value:
 
 
 
 
 
Customer relationships
10.3
 
$
149,380

 
$
146,200

Technology including internally developed software
6.6
 
21,244

 
18,078

Backlog
3.9
 
3,100

 
6,860

Covenants not to compete
4.8
 
416

 
1,040

Trade names
15.0
 
2,500

 

Total intangible assets, gross
 
 
176,640

 
172,178

Accumulated Amortization:
 
 
 
 
 
Customer relationships
 
 
(34,626
)
 
(24,870
)
Technology including internally developed software
 
 
(5,394
)
 
(10,879
)
Backlog
 
 
(2,648
)
 
(5,827
)
Covenants not to compete
 
 
(282
)
 
(